Download PDF
Semin Neurol 2014; 34(01): 061-069
DOI: 10.1055/s-0034-1372343
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Central Nervous System Diseases due to Opportunistic and Coinfections

Emily L. Ho
1   Department of Neurology, Harborview Medical Center, Seattle, Washington
,
Christina M. Marra
1   Department of Neurology, Harborview Medical Center, Seattle, Washington
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2014 (online)

    Permissions and Reprints

Abstract

With the widespread use of combination antiretroviral therapy (cART), the incidence of central nervous system (CNS) opportunistic infections and coinfections has significantly decreased. This review focuses on the clinical presentation, diagnostic laboratory and radiologic findings, as well as the treatment of neurosyphilis, progressive multifocal leukoencephalopathy, primary CNS lymphoma, and toxoplasmosis, which are CNS opportunistic infections and coinfections that are most relevant to clinicians in North America.

Keywords

human immunodeficiency virus - central nervous system - opportunistic infection - coinfection - lymphoma
 

  • References

  • 1 Mocroft AJ, Lundgren JD, d'Armino Monforte A , et al; The AIDS in Europe Study Group. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol 1997; 26 (2) 400-407
    CrossrefPubMedSearch in Google Scholar
  • 2 Garvey L, Winston A, Walsh J , et al; UK Collaborative HIV Cohort (CHIC) Study Steering Committee. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 2011; 18 (3) 527-534
    CrossrefPubMedSearch in Google Scholar
  • 3 Vivithanaporn P, Heo G, Gamble J , et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 2010; 75 (13) 1150-1158
    CrossrefPubMedSearch in Google Scholar
  • 4 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2011. Atlanta, GA: Department of Health and Human Services; 2012
    Search in Google Scholar
  • 5 Van de Laar M, Spiteri G. Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. Euro Surveill 2012; 17 (29) 20225
    PubMedSearch in Google Scholar
  • 6 Tucker JD, Yin YP, Wang B, Chen XS, Cohen MS. An expanding syphilis epidemic in China: epidemiology, behavioural risk and control strategies with a focus on low-tier female sex workers and men who have sex with men. Sex Transm Infect 2011; 87 (Suppl. 02) ii16-ii18
    PubMedSearch in Google Scholar
  • 7 Buchacz K, Klausner JD, Kerndt PR , et al. HIV incidence among men diagnosed with early syphilis in Atlanta, San Francisco, and Los Angeles, 2004 to 2005. J Acquir Immune Defic Syndr 2008; 47 (2) 234-240
    CrossrefPubMedSearch in Google Scholar
  • 8 Gao L, Zhang L, Jin Q. Meta-analysis: prevalence of HIV infection and syphilis among MSM in China. Sex Transm Infect 2009; 85 (5) 354-358
    CrossrefPubMedSearch in Google Scholar
  • 9 Davis LE, Schmitt JW. Clinical significance of cerebrospinal fluid tests for neurosyphilis. Ann Neurol 1989; 25 (1) 50-55
    CrossrefPubMedSearch in Google Scholar
  • 10 Rolfs RT, Joesoef MR, Hendershot EF , et al; The Syphilis and HIV Study Group. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med 1997; 337 (5) 307-314
    CrossrefPubMedSearch in Google Scholar
  • 11 Marra CM, Tantalo LC, Maxwell CL, Ho EL, Sahi SK, Jones T. The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sex Transm Dis 2012; 39 (6) 453-457
    CrossrefPubMedSearch in Google Scholar
  • 12 Marra CM, Maxwell CL, Collier AC, Robertson KR, Imrie A. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7: 37
    CrossrefPubMedSearch in Google Scholar
  • 13 Marra CM, Maxwell CL, Smith SL , et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004; 189 (3) 369-376
    CrossrefPubMedSearch in Google Scholar
  • 14 Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008; 22 (10) 1145-1151
    CrossrefPubMedSearch in Google Scholar
  • 15 Marra CM, Tantalo LC, Maxwell CL, Dougherty K, Wood B. Alternative cerebrospinal fluid tests to diagnose neurosyphilis in HIV-infected individuals. Neurology 2004; 63 (1) 85-88
    CrossrefPubMedSearch in Google Scholar
  • 16 Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis 2010; 37 (5) 283-287
    PubMedSearch in Google Scholar
  • 17 Rupprecht TA, Kirschning CJ, Popp B , et al. Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2. Infect Immun 2007; 75 (9) 4351-4356
    CrossrefPubMedSearch in Google Scholar
  • 18 Libois A, De Wit S, Poll B , et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis 2007; 34 (3) 141-144
    CrossrefPubMedSearch in Google Scholar
  • 19 Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 2009; 48 (6) 816-821
    CrossrefPubMedSearch in Google Scholar
  • 20 Wang YJ, Chi CY, Chou CH , et al. Syphilis and neurosyphilis in human immunodeficiency virus-infected patients: a retrospective study at a teaching hospital in Taiwan. J Microbiol Immunol Infect 2012; 45 (5) 337-342
    CrossrefPubMedSearch in Google Scholar
  • 21 Centers for Disease Control. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep 2010; 59 (RR–12): 1-110
    PubMedSearch in Google Scholar
  • 22 Hook III EWIII, Baker-Zander SA, Moskovitz BL, Lukehart SA, Handsfield HH. Ceftriaxone therapy for asymptomatic neurosyphilis. Case report and Western blot analysis of serum and cerebrospinal fluid IgG response to therapy. Sex Transm Dis 1986; 13 (3, Suppl): 185-188
    CrossrefPubMedSearch in Google Scholar
  • 23 Gentile JH, Viviani C, Sparo MD, Arduino RC. Syphilitic meningomyelitis treated with ceftriaxone: case report. Clin Infect Dis 1998; 26 (2) 528
    CrossrefPubMedSearch in Google Scholar
  • 24 Milger K, Fleig V, Kohlenberg A, Discher T, Lohmeyer J. Neurosyphilis manifesting with unilateral visual loss and hyponatremia: a case report. BMC Infect Dis 2011; 11: 17
    CrossrefPubMedSearch in Google Scholar
  • 25 Shann S, Wilson J. Treatment of neurosyphilis with ceftriaxone. Sex Transm Infect 2003; 79 (5) 415-416
    CrossrefPubMedSearch in Google Scholar
  • 26 Marra CM, Boutin P, McArthur JC , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000; 30 (3) 540-544
    CrossrefPubMedSearch in Google Scholar
  • 27 Dobbin JM, Perkins JH. Otosyphilis and hearing loss: response to penicillin and steroid therapy. Laryngoscope 1983; 93 (12) 1540-1543
    CrossrefPubMedSearch in Google Scholar
  • 28 Linstrom CJ, Gleich LL. Otosyphilis: diagnostic and therapeutic update. J Otolaryngol 1993; 22 (6) 401-408
    PubMedSearch in Google Scholar
  • 29 McLeish WM, Pulido JS, Holland S, Culbertson WW, Winward K. The ocular manifestations of syphilis in the human immunodeficiency virus type 1-infected host. Ophthalmology 1990; 97 (2) 196-203
    CrossrefPubMedSearch in Google Scholar
  • 30 Kiss S, Damico FM, Young LH. Ocular manifestations and treatment of syphilis. Semin Ophthalmol 2005; 20 (3) 161-167
    CrossrefPubMedSearch in Google Scholar
  • 31 Tucker JD, Li JZ, Robbins GK , et al. Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sex Transm Infect 2011; 87 (1) 4-8
    CrossrefPubMedSearch in Google Scholar
  • 32 French P, Gomberg M, Janier M, Schmidt B, van Voorst Vader P, Young H ; IUST. IUSTI: 2008 European Guidelines on the Management of Syphilis. Int J STD AIDS 2009; 20 (5) 300-309
    CrossrefPubMedSearch in Google Scholar
  • 33 Kingston M, French P, Goh B , et al; Syphilis Guidelines Revision Group 2008, Clinical Effectiveness Group. UK National Guidelines on the Management of Syphilis 2008. Int J STD AIDS 2008; 19 (11) 729-740
    CrossrefPubMedSearch in Google Scholar
  • 34 Moore JE, Gieske M. Syphilitic iritis. A study of 249 patients. Am J Ophthalmol 1931; 14: 110-126
    CrossrefPubMedSearch in Google Scholar
  • 35 Musher DM. Syphilis, neurosyphilis, penicillin, and AIDS. J Infect Dis 1991; 163 (6) 1201-1206
    CrossrefPubMedSearch in Google Scholar
  • 36 Inungu J, Morse A, Gordon C. Neurosyphilis during the AIDS epidemic, New Orleans, 1990-1997. [letter] J Infect Dis 1998; 178 (4) 1229
    CrossrefPubMedSearch in Google Scholar
  • 37 Shalaby IA, Dunn JP, Semba RD, Jabs DA. Syphilitic uveitis in human immunodeficiency virus-infected patients. Arch Ophthalmol 1997; 115 (4) 469-473
    CrossrefPubMedSearch in Google Scholar
  • 38 Lukehart SA, Hook III EWIII, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 1988; 109 (11) 855-862
    CrossrefPubMedSearch in Google Scholar
  • 39 Tramont EC. Persistence of Treponema pallidum following penicillin G therapy. Report of two cases. JAMA 1976; 236 (19) 2206-2207
    CrossrefPubMedSearch in Google Scholar
  • 40 Gordon SM, Eaton ME, George R , et al. The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection. N Engl J Med 1994; 331 (22) 1469-1473
    CrossrefPubMedSearch in Google Scholar
  • 41 Malone JL, Wallace MR, Hendrick BB , et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent serologic relapse after therapy. Am J Med 1995; 99 (1) 55-63
    CrossrefPubMedSearch in Google Scholar
  • 42 Dibbern Jr DA, Ray SC. Recrudescence of treated neurosyphilis in a patient with human immunodeficiency virus. Mayo Clin Proc 1999; 74 (1) 53-56
    CrossrefPubMedSearch in Google Scholar
  • 43 Marra CM, Longstreth Jr WT, Maxwell CL, Lukehart SA. Resolution of serum and cerebrospinal fluid abnormalities after treatment of neurosyphilis. Influence of concomitant human immunodeficiency virus infection. Sex Transm Dis 1996; 23 (3) 184-189
    CrossrefPubMedSearch in Google Scholar
  • 44 Marra CM, Maxwell CL, Tantalo L , et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter?. Clin Infect Dis 2004; 38 (7) 1001-1006
    CrossrefPubMedSearch in Google Scholar
  • 45 Centers for Disease Control and Prevention (CDC). Symptomatic early neurosyphilis among HIV-positive men who have sex with men—four cities, United States, January 2002-June 2004. MMWR Morb Mortal Wkly Rep 2007; 56 (25) 625-628
    PubMedSearch in Google Scholar
  • 46 Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127 (4) 467-470
    CrossrefPubMedSearch in Google Scholar
  • 47 Egli A, Infanti L, Dumoulin A , et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199 (6) 837-846
    CrossrefPubMedSearch in Google Scholar
  • 48 Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5 (1) 49-73
    PubMedSearch in Google Scholar
  • 49 Tan CS, Ellis LC, Wüthrich C , et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 2010; 84 (18) 9200-9209
    CrossrefPubMedSearch in Google Scholar
  • 50 Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4 (1) 59-68
    CrossrefPubMedSearch in Google Scholar
  • 51 Koralnik IJ, Wüthrich C, Dang X , et al. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57 (4) 576-580
    CrossrefPubMedSearch in Google Scholar
  • 52 Wüthrich C, Dang X, Westmoreland S , et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009; 65 (6) 742-748
    CrossrefPubMedSearch in Google Scholar
  • 53 Mascarello M, Lanzafame M, Lattuada E, Concia E, Ferrari S. Progressive multifocal leukoencephalopathy in an HIV patient receiving successful long-term HAART. J Neurovirol 2011; 17 (2) 196-199
    CrossrefPubMedSearch in Google Scholar
  • 54 Manfredi R, Piergentili B, Marinacci G, Calza L. Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies. Int J STD AIDS 2012; 23 (3) e35-e38
    CrossrefPubMedSearch in Google Scholar
  • 55 Berenguer J, Miralles P, Arrizabalaga J , et al; GESIDA 11/99 Study Group. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36 (8) 1047-1052
    CrossrefPubMedSearch in Google Scholar
  • 56 Küker W, Mader I, Nägele T , et al. Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control. Eur J Neurol 2006; 13 (8) 819-826
    CrossrefPubMedSearch in Google Scholar
  • 57 Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, Davis LE, Gilden DH. The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol 1995; 37 (6) 784-790
    CrossrefPubMedSearch in Google Scholar
  • 58 Kriegstein AR, Shungu DC, Millar WS , et al. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (“chasing the dragon”). Neurology 1999; 53 (8) 1765-1773
    CrossrefPubMedSearch in Google Scholar
  • 59 Langford TD, Letendre SL, Marcotte TD , et al; HNRC Group. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002; 16 (7) 1019-1029
    CrossrefPubMedSearch in Google Scholar
  • 60 Rackstraw S, Meadway J, Bingham J, Al-Sarraj S, Everall I. An emerging severe leukoencephalopathy: is it due to HIV disease or highly active antiretroviral therapy?. Int J STD AIDS 2006; 17 (3) 205-207
    CrossrefPubMedSearch in Google Scholar
  • 61 Costello DJ, Gonzalez RG, Frosch MP. Case records of the Massachusetts General Hospital. Case 18-2011. A 35-year-old HIV-positive woman with headache and altered mental status. N Engl J Med 2011; 364 (24) 2343-2352
    CrossrefPubMedSearch in Google Scholar
  • 62 Zaffiri L, Verma R, Struzzieri K, Monterroso J, Batts DH, Loehrke ME. Immune reconstitution inflammatory syndrome involving the central nervous system in a patient with HIV infection: a case report and review of literature. New Microbiol 2013; 36 (1) 89-92
    PubMedSearch in Google Scholar
  • 63 Venkataramana A, Pardo CA, McArthur JC , et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006; 67 (3) 383-388
    CrossrefPubMedSearch in Google Scholar
  • 64 Berger JR, Aksamit AJ, Clifford DB , et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80 (15) 1430-1438
    CrossrefPubMedSearch in Google Scholar
  • 65 Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43 (8) 4175-4177
    CrossrefPubMedSearch in Google Scholar
  • 66 Falcó V, Olmo M, del Saz SV , et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 2008; 49 (1) 26-31
    CrossrefPubMedSearch in Google Scholar
  • 67 Engsig FN, Hansen AB, Omland LH , et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199 (1) 77-83
    CrossrefPubMedSearch in Google Scholar
  • 68 Khanna N, Elzi L, Mueller NJ , et al; Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48 (10) 1459-1466
    CrossrefPubMedSearch in Google Scholar
  • 69 Dworkin MS, Wan PC, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 1999; 180 (3) 621-625
    CrossrefPubMedSearch in Google Scholar
  • 70 Fanjul F, Riveiro-Barciela M, Gonzalez J , et al. Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?. HIV Med 2012;
    PubMedSearch in Google Scholar
  • 71 Gasnault J, Costagliola D, Hendel-Chavez H , et al; ANRS 125 Trial Team. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS ONE 2011; 6 (6) e20967
    CrossrefPubMedSearch in Google Scholar
  • 72 De Luca A, Giancola ML, Ammassari A , et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 2000; 182 (4) 1077-1083
    CrossrefPubMedSearch in Google Scholar
  • 73 Post MJ, Yiannoutsos C, Simpson D , et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 1999; 20 (10) 1896-1906
    PubMedSearch in Google Scholar
  • 74 Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 2010; 81 (11) 1288-1291
    CrossrefPubMedSearch in Google Scholar
  • 75 Piza F, Fink MC, Nogueira GS, Pannuti CS, Oliveira AC, Vidal JE. JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: clinical presentations, associated factors with mortality and outcome. Braz J Infect Dis 2012; 16 (2) 153-156
    CrossrefPubMedSearch in Google Scholar
  • 76 Marra CM, Rajicic N, Barker DE , et al; Adult AIDS Clinical Trials Group 363 Team. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16 (13) 1791-1797
    CrossrefPubMedSearch in Google Scholar
  • 77 Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44 (3) 341-349
    CrossrefPubMedSearch in Google Scholar
  • 78 Bossolasco S, Calori G, Moretti F , et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005; 40 (5) 738-744
    CrossrefPubMedSearch in Google Scholar
  • 79 Yiannoutsos CT, Major EO, Curfman B , et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999; 45 (6) 816-821
    CrossrefPubMedSearch in Google Scholar
  • 80 García De Viedma D, Díaz Infantes M, Miralles P , et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis 2002; 34 (12) 1568-1575
    CrossrefPubMedSearch in Google Scholar
  • 81 Clifford DB, Nath A, Cinque P , et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 2013; 19 (4) 351-358
    CrossrefPubMedSearch in Google Scholar
  • 82 Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127 (Pt 9) 1970-1978
    CrossrefPubMedSearch in Google Scholar
  • 83 Marzocchetti A, Tompkins T, Clifford DB , et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73 (19) 1551-1558
    CrossrefPubMedSearch in Google Scholar
  • 84 Khanna N, Wolbers M, Mueller NJ , et al; Swiss HIV Cohort Study. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 2009; 83 (9) 4404-4411
    CrossrefPubMedSearch in Google Scholar
  • 85 Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72 (17) 1458-1464
    CrossrefPubMedSearch in Google Scholar
  • 86 Harrison DM, Newsome SD, Skolasky RL, McArthur JC, Nath A. Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol 2011; 238 (1-2) 81-86
    CrossrefPubMedSearch in Google Scholar
  • 87 Martin-Blondel G, Bauer J, Cuvinciuc V , et al. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection. Neurology 2013; 81 (11) 964-970
    CrossrefPubMedSearch in Google Scholar
  • 88 Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35 (10) 1250-1257
    CrossrefPubMedSearch in Google Scholar
  • 89 Hoffmann C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003; 74 (8) 1142-1144
    CrossrefPubMedSearch in Google Scholar
  • 90 D'Amico R, Sarkar S, Yusuff J, Azar E, Perlman DC. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis 2007; 39 (4) 347-350
    CrossrefPubMedSearch in Google Scholar
  • 91 Martinez JV, Mazziotti JV, Efron ED , et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006; 67 (9) 1692-1694
    CrossrefPubMedSearch in Google Scholar
  • 92 Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf . Accessed November 22, 2013
    PubMed
  • 93 Martin-Blondel G, Cuzin L, Delobel P , et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?. AIDS 2009; 23 (18) 2545-2546
    CrossrefPubMedSearch in Google Scholar
  • 94 So YT, Beckstead JH, Davis RL. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathological study. Ann Neurol 1986; 20 (5) 566-572
    CrossrefPubMedSearch in Google Scholar
  • 95 Ambinder RF. Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer 2001; 37 (10) 1209-1216
    CrossrefPubMedSearch in Google Scholar
  • 96 Kirk O, Pedersen C, Cozzi-Lepri A , et al; EuroSIDA Study Group. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98 (12) 3406-3412
    CrossrefPubMedSearch in Google Scholar
  • 97 Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19 (1) 14-19
    CrossrefPubMedSearch in Google Scholar
  • 98 Newell ME, Hoy JF, Cooper SG , et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 2004; 100 (12) 2627-2636
    CrossrefPubMedSearch in Google Scholar
  • 99 Kreisl TN, Panageas KS, Elkin EB, Deangelis LM, Abrey LE. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma 2008; 49 (9) 1710-1716
    CrossrefPubMedSearch in Google Scholar
  • 100 Pluda JM, Venzon DJ, Tosato G , et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993; 11 (6) 1099-1107
    PubMedSearch in Google Scholar
  • 101 Lowenthal DA, Straus DJ, Campbell SW, Gold JW, Clarkson BD, Koziner B. AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer 1988; 61 (11) 2325-2337
    CrossrefPubMedSearch in Google Scholar
  • 102 Remick SC, Diamond C, Migliozzi JA , et al. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature. Medicine (Baltimore) 1990; 69 (6) 345-360
    PubMedSearch in Google Scholar
  • 103 Goldstein JD, Zeifer B, Chao C , et al. CT appearance of primary CNS lymphoma in patients with acquired immunodeficiency syndrome. J Comput Assist Tomogr 1991; 15 (1) 39-44
    CrossrefPubMedSearch in Google Scholar
  • 104 Ruiz A, Ganz WI, Post MJ , et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. AJNR Am J Neuroradiol 1994; 15 (10) 1885-1894
    PubMedSearch in Google Scholar
  • 105 Lorberboym M, Wallach F, Estok L , et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998; 39 (8) 1366-1369
    PubMedSearch in Google Scholar
  • 106 Antinori A, Ammassari A, De Luca A , et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997; 48 (3) 687-694
    CrossrefPubMedSearch in Google Scholar
  • 107 Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis 2004; 38 (11) 1629-1632
    CrossrefPubMedSearch in Google Scholar
  • 108 Corcoran C, Rebe K, van der Plas H, Myer L, Hardie DR. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 2008; 42 (4) 433-436
    CrossrefPubMedSearch in Google Scholar
  • 109 Baumgartner JE, Rachlin JR, Beckstead JH , et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990; 73 (2) 206-211
    CrossrefPubMedSearch in Google Scholar
  • 110 Nagai H, Odawara T, Ajisawa A , et al. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 2010; 84 (6) 499-505
    CrossrefPubMedSearch in Google Scholar
  • 111 Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17 (12) 1787-1793
    CrossrefPubMedSearch in Google Scholar
  • 112 Hoffmann C, Tabrizian S, Wolf E , et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15 (16) 2119-2127
    CrossrefPubMedSearch in Google Scholar
  • 113 McGowan JP, Shah S. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS 1998; 12 (8) 952-954
    PubMedSearch in Google Scholar
  • 114 Aboulafia DM, Puswella AL. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS 2007; 21 (12) 900-907
    CrossrefPubMedSearch in Google Scholar
  • 115 Travi G, Ferreri AJ, Cinque P , et al. Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. J Clin Oncol 2012; 30 (10) e119-e121
    CrossrefPubMedSearch in Google Scholar
  • 116 Raez L, Cabral L, Cai JP , et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 1999; 15 (8) 713-719
    CrossrefPubMedSearch in Google Scholar
  • 117 Slobod KS, Taylor GH, Sandlund JT, Furth P, Helton KJ, Sixbey JW. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000; 356 (9240) 1493-1494
    CrossrefPubMedSearch in Google Scholar
  • 118 Aboulafia DM. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin Infect Dis 2002; 34 (12) 1660-1662
    CrossrefPubMedSearch in Google Scholar
  • 119 Bossolasco S, Falk KI, Ponzoni M , et al. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis 2006; 42 (4) e21-e25
    CrossrefPubMedSearch in Google Scholar
  • 120 Aboulafia DM, Ratner L, Miles SA, Harrington Jr WJ ; AIDS Associated Malignancies Clinical Trials Consortium. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma 2006; 6 (5) 399-402
    CrossrefPubMedSearch in Google Scholar
  • 121 Marretta L, Stocker H, Drauz D , et al. Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. Eur J Med Res 2011; 16 (5) 197-205
    CrossrefPubMedSearch in Google Scholar
  • 122 Antinori A, Larussa D, Cingolani A , et al; Italian Registry Investigative NeuroAIDS. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004; 39 (11) 1681-1691
    CrossrefPubMedSearch in Google Scholar
  • 123 Marra CM, Krone MR, Koutsky LA, Holmes KK. Diagnostic accuracy of HIV-associated central nervous system toxoplasmosis. Int J STD AIDS 1998; 9 (12) 761-764
    CrossrefPubMedSearch in Google Scholar
  • 124 Kiderlen TR, Liesenfeld O, Schürmann D, Schneider T. Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART). Eur J Clin Microbiol Infect Dis 2011; 30 (12) 1521-1525
    CrossrefPubMedSearch in Google Scholar
  • 125 Arendt G, von Giesen HJ, Hefter H, Neuen-Jacob E, Roick H, Jablonowski H. Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand 1999; 100 (3) 178-184
    PubMedSearch in Google Scholar
  • 126 Luft BJ, Hafner R, Korzun AH , et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 1993; 329 (14) 995-1000
    CrossrefPubMedSearch in Google Scholar
  • 127 Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327 (23) 1643-1648
    CrossrefPubMedSearch in Google Scholar
  • 128 Martin-Blondel G, Alvarez M, Delobel P , et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82 (6) 691-693
    CrossrefPubMedSearch in Google Scholar